Terms: = Ovarian cancer AND PDGFB, SIS, 5155, ENSG00000100311, FLJ12858, PDGF2, P01127, c-sis, SSV AND Treatment
11 results:
1. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
2. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
3. Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline ovarian Tumors by Integrative Polygenic Analytics.
Chang CM; Li YF; Lin HC; Lu KH; Lin TW; Liu LC; Su KM; Chang CC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921111
[TBL] [Abstract] [Full Text] [Related]
4. Osteopontin‑c isoform inhibition modulates ovarian cancer cell cisplatin resistance, viability and plasticity.
Brum MCM; Dos Santos Guimaraes I; Ferreira LB; Rangel LBA; Maia RC; Nestal De Moraes G; Gimba ERP
Oncol Rep; 2021 Feb; 45(2):652-664. PubMed ID: 33416171
[TBL] [Abstract] [Full Text] [Related]
5. Roads to the strategic targeting of ovarian cancer treatment.
Irusta G
Reproduction; 2021 Jan; 161(1):R1-R11. PubMed ID: 33112290
[TBL] [Abstract] [Full Text] [Related]
6. Novel extra cellular-like matrices to improve human ovarian grafting.
Abir R; Stav D; Taieb Y; Gabbay-Benziv R; Kirshner M; Ben-Haroush A; Freud E; Ash S; Yaniv I; Herman-Edelstein M; Fisch B; Shufaro Y
J Assist Reprod Genet; 2020 Sep; 37(9):2105-2117. PubMed ID: 32710268
[TBL] [Abstract] [Full Text] [Related]
7. pdgfb as a vascular normalization agent in an ovarian cancer model treated with a gamma-secretase inhibitor.
Pazos MC; Sequeira G; Bocchicchio S; May M; Abramovich D; Parborell F; Tesone M; Irusta G
J Cell Physiol; 2018 Aug; 233(8):5949-5961. PubMed ID: 29266203
[TBL] [Abstract] [Full Text] [Related]
8. Borderline tumors of the ovary: clinical course and prognostic factors.
Ewald-Riegler N; du Bois O; Fisseler-Eckhoff A; Kommoss F; Harter P; Traut A; Hils R; du Bois A
Onkologie; 2012; 35(1-2):28-33. PubMed ID: 22310342
[TBL] [Abstract] [Full Text] [Related]
9. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract] [Full Text] [Related]
10. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.
Davidson B; Givant-Horwitz V; Lazarovici P; Risberg B; Nesland JM; Trope CG; Schaefer E; Reich R
Clin Exp Metastasis; 2003; 20(7):621-31. PubMed ID: 14669793
[TBL] [Abstract] [Full Text] [Related]
11. Expression of platelet-derived growth factor (PDGF)-related transcripts and synthesis of biologically active PDGF-like proteins by human malignant epithelial cell lines.
Sariban E; Sitaras NM; Antoniades HN; Kufe DW; Pantazis P
J Clin Invest; 1988 Oct; 82(4):1157-64. PubMed ID: 2844850
[TBL] [Abstract] [Full Text] [Related]
